Sanofi-Aventis Jobs Profile

This profile is a brief introduction for people who may be considering working for Sanofi-Aventis and are seeking employment in the Pharmaceutical sector: pharmaceutical graduate jobs, pharmaceutical nurse advisors, pharmaceutical sales jobs, pharmaceutical training jobs, pharmaceutical sales management jobs, pharmaceutical marketing jobs, pharmaceutical executive jobs, pharmaceutical clinical research associates  or in the Pharmacy sector: Pharmacy Sales Jobs, OTC Sales Jobs, Pharmacy National Account Manager, Pharmacy Key Account Manager, Pharmacy Marketing Jobs. 

 

 

 

                       

 

About sanofi-aventis  
Sanofi-aventis is the world's 3rd largest pharmaceutical company and ranks number 1 in Europe, with around 100,000 employees worldwide. Global headquarters are located in Paris, France and the U.K. headquarters are in Guildford, Surrey.
Seven major therapeutic areas

Sanofi-aventis focuses its activities on seven major therapeutic areas:

  • cardiovascular
  • thrombosis
  • oncology
  • internal medicine
  • metabolic disorders
  • diseases of the central nervous system
  • and vaccines      

Great medicines for millions of patients
The sanofi-aventis portfolio of marketed products contains several medicines that are world leaders in their respective classes including: Clexane (enoxaparin sodium), Plavix (clopidogrel bisulfate), Telfast (fexofenadine), Aprovel (irbesartan), Eloxatin (oxaliplatin), Lantus (insulin glargine), Actonel (risedronate sodium) and Taxotere (docetaxel).

 

 

 
Because health matters  


Sherrie
Sanofi-Aventis Account Manager
01494 818 001
(Mon to Fri 0830 to 1800 hours)
sherrie@zenopa.com



Please contact the Account Manager for opportunities with this organisation

News

Sanofi-Aventis and BMS back NICE on vascular disease review
Sanofi-Aventis and Bristol-Myers Squibb (BMS) have expressed their support for a decision by the National Institute of Clinical Health and Excellence (NICE) to review its guidance on vascular disease.

Eli Lilly, Sanofi-Aventis and Novo Nordisk diabetes drugs 'to drive growth'
A research and advisory firm for the pharmaceutical and healthcare industry has suggested drugs from Eli Lilly.

Sanofi-Aventis atrial fibrillation drug 'under review' by EMEA
Sanofi-Aventis has reported that Multaq (dronedarone), its treatment candidate for patients with atrial fibrillation.

Sanofi-Aventis hands green award to UK factory
Sanofi-Aventis, the global pharmacy product supplier, has recognised a factory in the UK for its recent environmentally-friendly activities.

Sanofi-Aventis reports 'solid growth'
Sanofi-Aventis has announced its financial results for the second quarter of the 2008 fiscal year, with the company reporting "solid growth" during the period.


home | our clients | browse news | browse jobs | links | hotel directory | copyright © 2008 Zenopa Ltd | terms & conditions of use